CN107921284A - The therapeutical uses of barberry alkali preparation - Google Patents
The therapeutical uses of barberry alkali preparation Download PDFInfo
- Publication number
- CN107921284A CN107921284A CN201680049200.3A CN201680049200A CN107921284A CN 107921284 A CN107921284 A CN 107921284A CN 201680049200 A CN201680049200 A CN 201680049200A CN 107921284 A CN107921284 A CN 107921284A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- jamaicin
- method described
- analog
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 83
- 239000003513 alkali Substances 0.000 title claims description 26
- 235000016068 Berberis vulgaris Nutrition 0.000 title claims description 15
- 240000000724 Berberis vulgaris Species 0.000 title claims 2
- 230000001225 therapeutic effect Effects 0.000 title description 6
- WITLAWYGGVAFLU-UHFFFAOYSA-N 3-(6-methoxy-1,3-benzodioxol-5-yl)-8,8-dimethylpyrano[2,3-f]chromen-4-one Chemical compound C1=CC(C)(C)OC2=CC=C(C(C(C3=CC=4OCOC=4C=C3OC)=CO3)=O)C3=C21 WITLAWYGGVAFLU-UHFFFAOYSA-N 0.000 claims abstract description 180
- 231100000438 skin toxicity Toxicity 0.000 claims abstract description 22
- 230000007682 dermal toxicity Effects 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims description 50
- 239000000499 gel Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 29
- 239000003112 inhibitor Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 238000002626 targeted therapy Methods 0.000 claims description 21
- 206010015150 Erythema Diseases 0.000 claims description 20
- 238000012360 testing method Methods 0.000 claims description 19
- 239000006071 cream Substances 0.000 claims description 18
- 238000009169 immunotherapy Methods 0.000 claims description 18
- -1 BTK inhibitor Substances 0.000 claims description 15
- GLYPKDKODVRYGP-UHFFFAOYSA-O berberrubine Natural products C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GLYPKDKODVRYGP-UHFFFAOYSA-O 0.000 claims description 13
- GLYPKDKODVRYGP-UHFFFAOYSA-N burberrubine Natural products C12=CC=3OCOC=3C=C2CCN2C1=CC1=CC=C(OC)C(=O)C1=C2 GLYPKDKODVRYGP-UHFFFAOYSA-N 0.000 claims description 13
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 claims description 12
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 claims description 12
- 230000001900 immune effect Effects 0.000 claims description 11
- GYFSYEVKFOOLFZ-UHFFFAOYSA-N Berberrubine Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GYFSYEVKFOOLFZ-UHFFFAOYSA-N 0.000 claims description 10
- 108091000080 Phosphotransferase Proteins 0.000 claims description 10
- 102000020233 phosphotransferase Human genes 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229940121647 egfr inhibitor Drugs 0.000 claims description 9
- 102000038030 PI3Ks Human genes 0.000 claims description 8
- 108091007960 PI3Ks Proteins 0.000 claims description 8
- 206010033733 Papule Diseases 0.000 claims description 8
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 8
- 108091008611 Protein Kinase B Proteins 0.000 claims description 8
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 7
- 206010037888 Rash pustular Diseases 0.000 claims description 6
- 229940121649 protein inhibitor Drugs 0.000 claims description 6
- 239000012268 protein inhibitor Substances 0.000 claims description 6
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 5
- 229940124291 BTK inhibitor Drugs 0.000 claims description 5
- 229940125497 HER2 kinase inhibitor Drugs 0.000 claims description 5
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 claims description 5
- 229940124647 MEK inhibitor Drugs 0.000 claims description 5
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 5
- 206010043189 Telangiectasia Diseases 0.000 claims description 5
- 229940022399 cancer vaccine Drugs 0.000 claims description 5
- 238000009566 cancer vaccine Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 231100000321 erythema Toxicity 0.000 claims description 5
- 210000004209 hair Anatomy 0.000 claims description 5
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 5
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 5
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 5
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 5
- 239000003207 proteasome inhibitor Substances 0.000 claims description 5
- 208000009056 telangiectasis Diseases 0.000 claims description 5
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 claims description 4
- 206010034016 Paronychia Diseases 0.000 claims description 4
- 241000029132 Paronychia Species 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 claims description 4
- 238000005336 cracking Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 244000247747 Coptis groenlandica Species 0.000 claims description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 201000009240 nasopharyngitis Diseases 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000004088 foaming agent Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 25
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
- 238000011282 treatment Methods 0.000 description 20
- 241001083847 Berberis Species 0.000 description 16
- 239000003961 penetration enhancing agent Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000002500 effect on skin Effects 0.000 description 13
- 230000035699 permeability Effects 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 210000002615 epidermis Anatomy 0.000 description 11
- 230000001815 facial effect Effects 0.000 description 11
- 235000011187 glycerol Nutrition 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
- 229960001686 afatinib Drugs 0.000 description 9
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 9
- 125000000129 anionic group Chemical group 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 201000004700 rosacea Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 241001303601 Rosacea Species 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 5
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 5
- 229940093265 berberine Drugs 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
- 229960003415 propylparaben Drugs 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 5
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 4
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 4
- 229940043234 carbomer-940 Drugs 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000007390 skin biopsy Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 3
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 3
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 3
- 102000017578 LAG3 Human genes 0.000 description 3
- 101150030213 Lag3 gene Proteins 0.000 description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 102000016946 TWEAK Receptor Human genes 0.000 description 3
- 108010014401 TWEAK Receptor Proteins 0.000 description 3
- 244000299492 Thespesia populnea Species 0.000 description 3
- 235000009430 Thespesia populnea Nutrition 0.000 description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 229960005386 ipilimumab Drugs 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 208000017983 photosensitivity disease Diseases 0.000 description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 2
- 241001407408 Berberis fortunei Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000003325 Ilex Nutrition 0.000 description 2
- 241000209035 Ilex Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- QBUIDYLGKMWNEA-UHFFFAOYSA-O Palmatrubine Natural products COC1=C(OC)C=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=C1 QBUIDYLGKMWNEA-UHFFFAOYSA-O 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- SQNGFLZBHUXPNB-UHFFFAOYSA-N benzoic acid;butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)C1=CC=CC=C1 SQNGFLZBHUXPNB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 229940088503 dermalzone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007386 incisional biopsy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000003810 morphinanes Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010091078 rigin Proteins 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Pharmaceutical composition comprising jamaicin is used to treat dermal toxicity and the purposes of other skin disorders.
Description
Background technology
Red face related dermal illness (red face with identical symptom similitude and possible causes for pathological
Related skin disorder) include rosacea, acne vulgaris, seborrhea, photodermatitis and contact skin
It is scorching.The scope of these red face related conditions can be from thermal sensation and sensitive to the scorching hot of flush or strong sensitivity.With red face
The patient of related dermal illness usually reveals exquisite sensitivity to environment and local factor meter.The rosacea sample of steroids induction
Dermatitis (or steroids rosacea) is papular or pustular lesion (lesion), has erythema and an edemous substrate, companion or
Without telangiectasis, this is because topical steroids are applied to for a long time caused by face or topical steroids stop
The rebound patient's condition afterwards.
Dermal toxicity is known and targeted therapies or the relevant skin adverse events of immunotherapy, and related to red face
Skin disorder has similar symptom and possible causes for pathological.Targeted therapies such as EGF-R ELISA (EGFR) inhibitor,
More tyrosine kinase (MTK) inhibitor, mek inhibitor, phosphoinositide 3-kinase (PI3K) inhibitor, protein kinase B (AKT) suppression
It is preparation, BRAF inhibitor, HER2 inhibitor, more kinase angiogenesis inhibitors, mTOR inhibitors, ALK/c-met inhibitor, more
Kinases Abl inhibitor, BTK inhibitor, hdac inhibitor, proteasome inhibitor and Retinoid X Receptor (RXR) activator;
Immunotherapy such as cancer vaccine, cell factor reagent are (for example, granulocyte-macrophage colony stimutaing factor (GM-CSF), interference
Element and interleukin 2 (IL-2)), cell therapy is (for example, tumor infiltrating lymphocyte (TIL), φt cell receptor (TCR) work
Journey peripheral blood lymphocytes (PBL) and Chimeric antigen receptor (CAR) engineering PBL), immunologic test point protein inhibitor
(for example, PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, BTLA, VISTA and TIGIT) and immunologic test point albumen stimulant
(for example, CD28, ICOS, 4-1BB, OX40, BITR, CD27, TWEAKR, HVEM, TIM-1 and CD-40);Or any of the above-described therapy
Combination can induce toxic reaction, including papulopustular rash (papulopustular rash), plaque-like papule
(maculopapular rash), erythema, telangiectasis flush, paronychia and cracking, hair change, axersis, mucous membrane
Scorching, pruritus and hand-foot skin react, these can occur in the patient more than 90%, and be also possible to sense overlapping with bacterium
Dye, the bacterium such as staphylococcus aureus (Wollenberg, Kroth et al., Cutaneous side effects of
EGFR inhibitors--appearance and management,Dtsch Med Wochenschr 2010;
Lacouture, Maitland et al., A proposed EGFR inhibitor dermatologic adverse event-
specific grading scale from the MASCC skin toxicity study group,Support Care
Cancer,2010;Curry, Torres-Cabala et al., Dermatologic toxicities to targeted
cancer therapy:shared clinical and histologic adverse skin reactions,
International Journal of Dermatology,2014;Jeffrey S.Weber et al., Toxicities of
Immunotherapy for the Practitioner,Journal of Clinical Oncology,Vol.33,2015;
Grace K.Dy and Alex A.Adjei,Understanding,Recognizing,and Managing Toxicities
of Targeted Anticancer Therapies,CA Cancer J Clin,Vol.63,2013;Ahmad Tarhini,
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4Blockade
Therapy:The Underlying Mechanisms and Clinical Management,Scientifica,2013;J
Larkin et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated
Melanoma,N.Engl.J.Med.,Vol.373,2015).The histopathology of this dermal toxicity finds that display frequently involves
Inflammation simultaneously causes acneform eruptions.Papulopustular rash is in EGFR inhibitor such as Cetuximab (cetuximab) (83% trouble
Person) and Afatinib (90% patient), and mek inhibitor as take charge of it is beautiful for Buddhist nun (selumetinib) (93% patient) and
Sibutramine Hydrochloride is replaced in Buddhist nun (trametinib) (80% patient) therapy and reported frequently.Plaque-like papule more commonly with PI3K inhibitor
Such as example anti-CTLA-4 suppressions of BKM-120 (37% patient), MK2206 (52% patient) therapy, immunologic test point protein inhibitor
The easy Puli's nurse agate (ipilimumab) (33% patient) of preparation, anti-PD-1 inhibitor nivolumab (26% patient) or easy
The combination (patient more than 40%) of Puli's nurse agate and nivolimumab are described together.
Jamaicin (18,5,6- dihydro -9,10- dimethoxy benzo (g) -1,3- benzodioxoles of natural Huang
(5,6-a) quinolizine) it is the morphinane alkaloid being present in herbaceous plant, the herbaceous plant such as Coptis (coptis root
Stem), Cortex Phellodendri (phellodenron), radix scutellariae (Scutellaria baicalensis), leaf of Chinese ilex Chinese mahonia (Mahonia
) and berberis (berberis) aquifolium.It has been found that jamaicin and its derivative have antimicrobial and antimalarial
Disease activity.It can act on various pathogen, such as fungi, saccharomycete, parasite, bacterium and virus.
Jamaicin also has anti-inflammatory effect, but precise mechanism is unclear.
U.S. Patent number 6,440,465 is related to the topical skin preparations of the aminoglucose in emollient matrix, it contains barberry
Alkali, for treating psoriasis.U.S. Patent Publication No. 2005/0158404 is related to nutrition product, dietary supplements or drug regimen
Thing, it contains the jamaicin of VitAVitE, selenium, vitamin B6, zinc, chromium and herbal medicine source, for orally administering treatment
Acne.U.S. Patent number 6,974,799 be related to comprising tripeptides (n-palmitoyl-Gly-His-Lys) and tetrapeptide (N- palmityls-
Gly-Gln-Pro-Arg topical composition), for treating the visible signs of aging, including wrinkle, vergeture (stretch
Mark), livid ring around eye.Said preparation can contain other compositions, including jamaicin.In these inventions, jamaicin as it is numerous into
/ mono- by including and being not specified by its concentration.
U.S. Patent Publication 2004/0146539 is related to slim and toning Firm (tone-firming) anti-aging benefit
The local Halth-care composition at place, it can be used for treatment skin aging, wrinkle of skin, skin exfoliative (skin
Exfoliating), acne, rosacea and other skin problems.The composition of the invention includes antimicrobial, described anti-
Microorganism agent is selected from several medicaments, including jamaicin.In these Halth-care compositions, jamaicin is as one of numerous compositions quilt
Including, and it is not specified by its concentration.There is the 10% leaf of Chinese ilex Chinese mahonia emulsifiable paste containing 0.1% jamaicin
(RelievaTM, Apollo Pharmaceutical Canada Inc) it is used to treat psoriasis.
U.S. Patent Publication 2012/0165357 discloses the use that jamaicin is used to treat various red face related dermal illnesss
On the way, but without the specific preparation for disclosing any small bavin alkali that can effectively treat the specific patient's condition.
Therefore, there is still a need for exploitation is used to treating various red face related dermal illnesss and by targeted therapies and/or immune
The new effective method of the dermal toxicity of therapy induction.
The content of the invention
The present invention provides for treating and/or preventing red face related dermal illness and by targeted therapies and/or immune treatment
The pharmaceutical composition of the dermal toxicity of method induction.The preparation provided is based on emulsifiable paste (i.e. emulsifiable paste) preparation or based on gel
Preparation.
Especially, the present invention provides the pharmaceutical composition comprising jamaicin, wherein the composition be bag aqueous phase and
The cream preparation of oil phase.
In one embodiment, the concentration of the cream preparation Berberine provided is excellent between 0.01% to 10%
0.01% is selected between 0.3%w/w, more preferably 0.1% between 0.2%w/w, even more preferably 0.1% to 0.15%w/w it
Between, most preferably from about 0.12%w/w.
Unless expressly stated otherwise, otherwise when the application is with w/w form description amounts or concentration, the weight of every kind of component
With the gross weight meter of preparation.
The pharmaceutical composition of the present invention can also include penetration enhancer.
In one embodiment, penetration enhancer is anionic permeation enhancers.
In another embodiment, penetration enhancer includes60 and glycerine.
In one embodiment, jamaicin is unique pharmaceutical active in provided preparation.
In one embodiment, the pH of pharmaceutical composition of the invention is between about 4 to about 7, and more preferably from about 5.5.
In a preferred embodiment, the present invention provides include the jamaicin as unique pharmaceutical active
Pharmaceutical composition, wherein the concentration of the jamaicin 0.1% between 0.2%w/w, wherein the composition is bag aqueous phase
With the cream preparation of oil phase, wherein the composition includes penetration enhancer, preservative and stabilizer, and wherein described combination
The pH of thing is between about 4 to about 7.
In even more preferably embodiment, the present invention provides include the jamaicin as unique pharmaceutical active
Pharmaceutical composition, wherein the concentration of the jamaicin is about 0.12%w/w, wherein the composition is bag aqueous phase and oil phase
Cream preparation, wherein the composition includes penetration enhancer, preservative and stabilizer, and the pH of wherein described composition
It is about 5.5.
In another embodiment, the present invention provides the pharmaceutical composition comprising jamaicin, wherein the composition
It is the preparation based on gel, wherein the composition includes anionic permeation enhancers.
In a preferred embodiment, anionic permeation enhancers include lauryl sodium sulfate (SDS).
In one embodiment, in the pharmaceutical composition provided by the invention based on gel, about 90% jamaicin
Particle mean size be less than 10 μm.
In another embodiment, in the pharmaceutical composition provided by the invention based on gel, about 50% barberry
The particle mean size of alkali is less than 4 μm.
In one embodiment, the concentration of the preparation Berberine based on gel provided is 0.01% to 0.3%
Between w/w, more preferably 0.1% between 0.2%w/w, and even more preferably 0.1% between 0.15%w/w, and most preferably from about
0.12%w/w.
Present invention also offers the method for treating red face related dermal illness, it includes its patient to needs and applies pharmacy
Upper a effective amount of pharmaceutical composition of the invention.
In one embodiment, red face related dermal illness is selected from the group consisted of:Rosacea, common Cuo
Sore, seborrhea, photodermatitis, contact dermatitis, the rosacea sample dermatitis and epidermal growth factor of steroids induction
The skin disorder of acceptor (EGFR) inhibitor induction.
Present invention also offers treatment and/or prevent the side of dermal toxicity induced by targeted therapies and/or immunotherapy
Method, it includes the jamaicin and/or its biology equivalence analog using pharmaceutical effective amount to its patient of needs.
In preferred embodiments, the targeted therapies include by EGFR inhibitor, MTK inhibitor, mek inhibitor,
PI3K inhibitor, AKT inhibitor, BRAF inhibitor, HER2 inhibitor, more kinase angiogenesis inhibitors, mTOR inhibitors,
ALK/c-met inhibitor, more kinases Abl inhibitor, BTK inhibitor, hdac inhibitor, proteasome inhibitor and RXR excitements
The therapy that agent carries out.
In preferred embodiments, immunotherapy include by cancer vaccine, cell factor reagent (such as granulocyte-
Macrophage colony stimulatory factor (GM-CSF), interferon and interleukin 2 (IL-2)), cell therapy (such as tumour leaching
Moisten lymphocyte (TIL), the peripheral blood lymphocytes (PBL) and Chimeric antigen receptor (CAR) of φt cell receptor (TCR) engineering
The PBL of engineering), immunologic test point protein inhibitor (such as PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, BTLA,
VISTA and TIGIT) and immunologic test point albumen stimulant (such as CD28, ICOS, 4-1BB, OX40, BITR, CD27,
TWEAKR, HVEM, TIM-1 and CD-40) carry out therapy.
In a preferred embodiment, in the form of local medicine composition to patient apply jamaicin and/or its
Biology equivalence analog.
Brief description of the drawings
This patent or application documents contain an at least color drawings.This patent or patent application with color drawings are public
The copy opened will provide as requested and under conditions of necessary expense is paid by Patent Office.
Fig. 1 is that small bavin alkali (ng/cm is permeated in the accumulation of the barberry alkali preparation of six kinds of tests2)-time diagram.
Fig. 2 is that small bavin alkali (ng/cm is permeated in the accumulation of three kinds of jamaicin gel mixed suspension preparations (G22, G23 and G24)2)-when
Between scheme.
Fig. 3 is the figure of h and E (H&E) dyeing for the bilateral skin biopsy for showing patient's nasolabial groove gauffer, described
Patient receives Afatinib and in its facial side local application gel preparation (G23).
Fig. 4 is the figure of h and E (H&E) dyeing for the bilateral skin biopsy for showing patient's nasolabial groove gauffer, described
Patient receives EGFR inhibitor Afatinib and in its facial opposite side local application vehicle gel (G23 of no jamaicin).
Fig. 5 is papule counting-time diagram of patient, and the patient receives Afatinib and in its facial side local application
Gel preparation (G23) and (* represents to pass through Weir in its facial opposite side local application vehicle gel (G23 of no jamaicin)
The gloomy signed rank test in Cork (Wilcoxon Signed Rank test), P<0.05).
Fig. 6 is warts counting-time diagram of patient, and the patient receives Afatinib and in its facial side local application
Gel preparation (G23) and (* represents to pass through Weir in its facial opposite side local application vehicle gel (G23 of no jamaicin)
The gloomy signed rank test in Cork, P<0.05).
Fig. 7 is tale (papule and warts)-time diagram of patient, and the patient receives Afatinib and in its face one
Side local application gel preparation (G23) and in its facial opposite side local application vehicle gel (G23 of no jamaicin) (* table
Show by Wilcoxen signed rank test, P<0.05).
Embodiment
Depending on the particular condition treated, jamaicin can skin permeation be effectively important.Jamaicin is a kind of parent
Aqueous compounds (distribution coefficient in octanol-water system is 1.07), this causes jamaicin to be difficult to penetrate through cuticula
(SC) target site of the dermal toxicity of red face related dermal illness or targeted therapies induction, example may occur wherein with arrival
Such as, corium or epidermis.In addition, jamaicin is quite solvable (solubility 1.57mg/ml), therefore target will be fast released
In cell, cause interim effect.
Therefore, the present invention provides the pharmaceutical composition that jamaicin permeability improves, for treating and/or preventing red face phase
Close skin disorder and the dermal toxicity induced by targeted therapies and/or immunotherapy.The preparation provided be based on emulsifiable paste (i.e.
Emulsifiable paste) preparation or the preparation based on gel.
Especially, the present invention provides the pharmaceutical composition comprising jamaicin, wherein the composition be bag aqueous phase and
The cream preparation of oil phase.
Because the cream preparation of the present invention can promote jamaicin to infiltrate into skin, the jamaicin of relatively small amount is just
Sufficiently achieve expected therapeutic effect.In one embodiment, the gross weight based on preparation is small in the cream preparation provided
The concentration of bark of a cork tree alkali 0.01% between 10%w/w, preferably 0.01% to 0.3%w/w, more preferably 0.1% to 0.2%w/w it
Between, even more preferably 0.1% between 0.15%w/w, most preferably from about 0.12%w/w.
The pharmaceutical composition of the present invention can also include penetration enhancer.
In one embodiment, penetration enhancer is anionic permeation enhancers.For example, anionic permeation enhancers can
To include lauryl sodium sulfate (SDS).
In another embodiment, penetration enhancer includes60 and glycerine.The cream preparation of the present invention is preferred
Including60 and glycerine as penetration enhancer.When identical penetration enhancer is used in non-cream preparation, they
Permeability will not be caused to improve, this shows on unique there are some based on the preparation of emulsifiable paste.
In one embodiment, jamaicin is unique pharmaceutical active in provided preparation.Even if provided
The component of preparation be probably for the purpose in addition to treating the dermal toxicity induced by targeted therapies or immunotherapy
Active component in prior art preparation, but as long as the component is not induced with being enough effectively treatment by targeted therapies or immunotherapy
Dermal toxicity amount exist, then for the purpose of the preparation provided, be still construed as drug excipient.
In one embodiment, the pH of pharmaceutical composition of the invention is about 4 to about 7, more preferably from about 5.5.
In a preferred embodiment, the present invention provides include medicine jamaicin as unique pharmaceutical active
Compositions, wherein the concentration of the jamaicin 0.1% between 0.2%w/w, wherein the composition for bag aqueous phase and
The cream preparation of oil phase, wherein the composition includes penetration enhancer, preservative and stabilizer, and wherein described composition
PH be about 4 to about 7.
In even more preferably embodiment, the present invention provides comprising jamaicin as unique pharmaceutical active
Pharmaceutical composition, wherein the concentration of the jamaicin is about 0.12%w/w, wherein the composition is bag aqueous phase and oil phase
Cream preparation, wherein the composition includes penetration enhancer, preservative and stabilizer, and the pH of wherein described composition is
About 5.5.
It is very astonishing and surprisingly it has been found that compared with non-emulsifiable paste barberry alkali preparation, cream preparation of the invention
With excellent permeability.
In another embodiment, the present invention provides the pharmaceutical composition comprising jamaicin, wherein the composition
It is the preparation based on gel, wherein the composition includes anionic permeation enhancers.
In a preferred embodiment, anionic permeation enhancers include lauryl sodium sulfate (SDS).Including
SDS is hydrophobic (in octanol-water system point as the preparation based on gel that anionic permeation enhancers cause to be provided
Distribution coefficient is 50.1), and to have significantly lower solubility, is about 0.011mg/ml, jamaicin is sustained to target cell
In, cause release profiles to extend.
Find in the present invention, under the pH between 4 to 7, in the presence of SDS, jamaicin solubility range is certainly
0.01 to 0.06mg/ml, i.e. it is 25 to 150 times lower than water-based barberry alkali solubility (1.57mg/ml), and in 5.5 times phases of pH
To relatively low.
It was surprisingly found that all tests penetration enhancer (SDS, glycerine, propane diols, PEG 400, ethanol and) in, added in the preparation based on gel in permeability promotion and maximum epidermis and corium that SDS causes maximum
The local concentration increase of jamaicin.
In one embodiment, in the pharmaceutical composition provided by the invention based on gel, about 90% jamaicin
Particle mean size be less than 10 μm.
In another embodiment, in the pharmaceutical composition provided by the invention based on gel, about 50% barberry
The particle mean size of alkali is less than 4 μm.
It was also surprisingly found that in the preparation based on gel, it is proportionate between the amount and permeability of SDS, and
It is negatively correlated between the size and permeability of jamaicin.
Because the present invention the preparation based on gel jamaicin can be promoted to infiltrate into skin, relatively small amount it is small
Bark of a cork tree alkali just sufficiently achieves required therapeutic effect.In one embodiment, the gross weight based on preparation, provided based on solidifying
The concentration of the preparation Berberine of glue is 0.01% to 0.3%w/w, more preferably 0.1% to 0.2%w/w, even more preferably
0.1% and 0.15%w/w, most preferably from about 0.12%w/w.
Present invention also offers the method for treating red face related dermal illness, it includes its patient to needs and applies pharmacy
Upper a effective amount of pharmaceutical composition of the invention.
In one embodiment, red face related dermal illness is selected from the group consisted of:Rosacea, common Cuo
Sore, seborrhea, photodermatitis, contact dermatitis, the rosacea sample dermatitis and epidermal growth factor of steroids induction
The skin disorder of acceptor (EGFR) inhibitor induction.
Present invention also offers treatment and/or prevent the side of dermal toxicity induced by targeted therapies and/or immunotherapy
Method, it includes the pharmaceutical composition of the invention using pharmaceutical effective amount to its patient of needs.
In one embodiment, the targeted therapies are selected from the group consisted of:EGFR, more tyrosine kinase
(MTK), MEK, phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), BRAF inhibitor, HER2 inhibitor, more kinases blood
Pipe formation inhibitor, mTOR inhibitors, ALK/c-met inhibitor, more kinases Abl inhibitor, BTK inhibitor, hdac inhibitor,
Proteasome inhibitor and rxr agonist;The immunotherapy is selected from the group consisted of:Cancer vaccine, cell factor examination
Agent (such as granulocyte-macrophage colony stimutaing factor (GM-CSF), interferon and interleukin 2 (IL-2)), cell are treated
Method (such as tumor infiltrating lymphocyte (TIL), φt cell receptor (TCR) engineering peripheral blood lymphocytes (PBL) and be fitted together to
Antigen receptor (CAR) engineering PBL), immunologic test point protein inhibitor (such as PD-1, PD-L1, CTLA-4, TIM-3,
LAG-3, BTLA, VISTA and TIGIT) and immunologic test point albumen stimulant (such as CD28, ICOS, 4-1BB, OX40, BITR,
CD27, TWEAKR, HVEM, TIM-1 and CD-40);And the dermal toxicity induced by targeted therapies and/or immunotherapy
Selected from group consisting of:Papulopustular rash, plaque-like papule, erythema, telangiectasis flush, paronychia and cracking, hair
Send out change, axersis, catarrh, pruritus and hand-foot skin reaction.
Measure epidermis, corium and receiver by the following method (it refers to the container filled with PBS with skin contact)
The concentration of Berberine.Franz diffusion cells are substantially that one piece of skin is clipped between two fixtures.By medicinal application in skin
The side (top) of skin, and measure drug concentration in the receiving portion (bottom) of device.
As used herein, term " permeability " refer to from by formulation application in skin for a period of time after, be present in every gram
The amount of jamaicin in epidermis or dermal tissue, or the every cm being present in receiver2The amount of the jamaicin of skin.
The amount of the medicine measured in the receiver represents to penetrate through the total amount of the SC of skin, epidermis and dermal zone.This
The pharmaceutical composition of invention has the permeability improved, and the preferred scope of permeability is as follows:
Epidermis:The μ g jamaicins of per gram of tissue 0.4 to 4000
Corium:The μ g jamaicins of per gram of tissue 0.003 to 30
Receiver:Every 1 × 1cm2The μ g jamaicins of skin 0.0001 to 1.
Table 1 below lists the various composition that may be used in the composition of the present invention.But, there is provided the list is only used for
Improving eyesight, rather than limit the scope of the invention.In addition, different component/excipient can be worked in a manner of more than one,
Such as it may be used as penetration enhancer, emulsifying agent, wetting agent etc..
Table 1
As used herein, term " jamaicin " refers to two between 5,6- dihydro -9,10- dimethoxy benzos (g) -1,3- benzo
Oxole (5,6-a) quinolizine.Present invention also contemplates that the purposes of jamaicin analog, the jamaicin analog include but
It is not limited to jateorrhizine (jatrorrhizine), palmatine (palmatine), coptisine, 9- demethyls jamaicin, 9- demethyls
Palmatine, 13- hydroxyls jamaicin, berberrubine (berberrubine), the red alkali of palmatine (palmatrubine), 9-O- ethyls
Berberrubine, 9-O- ethyl -13- ethyls berberrubine, 13- methyl dihydroberberine N- methyl salts, Tetrahydro-proto-berberines and its
The pharmaceutically acceptable salt of N- methyl salts, 9- lauryl berberrubine chlorides and all these compounds.
As used herein, term " pharmaceutically acceptable salt " includes acid or basic group salt.It is pharmaceutically acceptable
Salt example include derived from inorganic acid salt, the inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, a hydrogen carbonic acid, phosphorus
Acid, a hydrogen phosphoric acid, dihydrogen phosphoric acid, sulfuric acid, a hydrosulphuric acid, hydroiodic acid or phosphorous acid etc., and derived from the organic of relative nontoxic
The salt of acid, the organic acid such as acetic acid of the relative nontoxic;Propionic acid;Isobutyric acid;Maleic acid;Malonic acid;Benzoic acid;Butanedioic acid;It is pungent
Diacid;Fumaric acid;Mandelic acid;Phthalic acid;Benzene sulfonic acid;Toluenesulfonic acid, including p-methyl benzenesulfonic acid, m-toluene sulfonic acid and adjacent first
Benzene sulfonic acid;Citric acid;Tartaric acid;Methanesulfonic acid;Etc..Further include for example arginic salt of amino acid etc., and the salt of organic acid, institute
State organic acid such as glucuronic acid or galacturonic acid etc..
As used herein, term " treatment " includes suppressing disease or the patient's condition, causes the order of severity and/or frequency drop of symptom
It is low, symptom and/or potential cause are eliminated, prevents symptom and/or the generation of its potential cause, mitigates and/or improve the shape of patient
Condition.Therefore, the particular condition in prevention susceptible individual is included with composition of the present invention " treatment " patient, and management has
The individual of clinical symptoms is to suppress or cause the regression of conditions or diseases, and maintains current state and/or prevention illness or disease
The progress of disease.Treatment can include prevention, treatment or cure.
As used herein, the term of compound of the invention and/or pharmaceutical composition " pharmaceutical effective amount " refers to be enough
It is suitable for reasonable benefit/Hazard ratio of any therapeutic treatment to treat, suppress, mitigate or prevent various red face related dermal illnesss
The compound of (dermal toxicity for including but not limited to targeted therapies induction) and/or the amount of composition.It will be understood, however, that
The compound of the present invention and/or daily total dosage of composition will be determined within a reasonable range of medical judgment by attending doctor.
Many factors will be depended on for the specific effective dose level of any specific patient, including the illness treated and illness is tight
Weight degree;The activity of used particular compound;Used concrete composition;The age of patient, weight, general health shape
Condition, gender and diet;The discharge rate of time of application, route of administration and used particular compound;The duration for the treatment of;
Combine with used particular compound or medicine used at the same time;And well-known similar factor in medical domain.Example
Such as, those skilled in the art are known, to start composition dosage less than the level needed for expected therapeutic effect of realizing, and gradually increase
Add dosage until realizing Expected Results.
Pharmaceutical composition can also include pharmaceutically acceptable carrier, and can be solid or liquid form, including
But it is not limited to tablet, pulvis, capsule, pill, solution, supensoid agent, elixir, emulsion, gelling agent, cream, patch or bolt
Agent includes rectum and urethral suppositories.
As used herein, term " pharmaceutically acceptable carrier " refers to pharmaceutically acceptable material, composition or matchmaker
Jie's thing, such as liquid or solid filler, diluent, excipient, solvent or encapsulating material.Pharmaceutically acceptable carrier and group
Other compositions, the method for application of compound are compatible, without being damaged to patient.Pharmaceutically acceptable carrier can be water-based
Or it is non-aqueous.Pharmaceutically acceptable carrier includes natural gum, starch, sugar, cellulosic material and its mixture.It can be used as medicine
Some examples of the material of acceptable carrier include but not limited on:(a) it is sugared, such as lactose, dextrose and saccharose;(b)
Starch, such as cornstarch and farina;(c) cellulose and its derivates, as sodium carboxymethylcellulose, ethyl cellulose and
Cellulose acetate;(d) tragacanth gum powder;(e) malt;(f) gelatin;(g) talcum powder;(h) excipient, such as cocoa butter and suppository
Wax;(i) it is oily, such as peanut oil, cotton seed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil;(g) glycol, such as the third two
Alcohol;(k) polyalcohol, such as glycerine, sorbierite, mannitol and polyethylene glycol;(l) ester, such as ethyl oleate and ethyl laurate;
(m) agar;(n) buffer, such as magnesium hydroxide, aluminium hydroxide, boric acid and Boratex and phosphate buffer;(o) alginic acid;
(p) pyrogen-free water;(q) isotonic saline solution;(r) Ringer's solution;(s) ethanol;(t) phosphate buffer solution;And (u) is suitable for
Other non-toxic compatible materials used in pharmaceutical composition.
Any-mode known in the art can be used to apply composition of the invention, including but not limited to oral, nasal cavity,
Parenteral, local, transdermal or rectal administration approach.Preferably, composition is suitable for orally or topically applying.For example, composition
Active ingredient can be formulated for preparing tablet, capsule, pill, lozenge (troche), sugar together with suitable excipient
Lozenge (lozenge), solution, pulvis or granule, supensoid agent, hard or soft capsule, patch and other any suitable shapes
Formula.
Present invention also offers treatment and/or prevent the side of dermal toxicity induced by targeted therapies and/or immunotherapy
Method, it includes the jamaicin or its biology equivalence analog to its patient of needs using pharmaceutical effective amount.
Present invention also offers treatment and/or prevent the side of dermal toxicity induced by targeted therapies and/or immunotherapy
Method, it includes the local medicine composition to infected local skin application pharmaceutical effective amount, topical remedy's combination
Thing includes jamaicin or its biology equivalence analog.
In one embodiment, local medicine composition for lotion, cream, ointment, paste, gel, spray,
Supensoid agent, emulsion, foaming agent, patch, the form of pulvis and liniment.
In one embodiment, local medicine composition includes at least 0.02%w/w, and preferably from about 0.1% to about 2%w/
The jamaicin of w or its biology equivalence analog, wherein the amount is with the gross weight meter of composition.
In one embodiment, the biology equivalence analog of jamaicin or jamaicin is main pharmaceutically acceptable
Active component.
In one embodiment, the biology equivalence analog of jamaicin or jamaicin is unique pharmaceutically acceptable
Active component.
Following example illustrate some aspects of the present invention.Embodiment is not meant to limit this hair in any way
It is bright.
Embodiment 1
The mouse skin penetration study of barberry alkali preparation
Compare following six kinds of barberry alkali preparations:C8,0.125%, 0.3%, G22, G23 and G24.
Preparation
Preparation is as follows:
C8 (preparation based on emulsifiable paste):
Water phase
Jamaicin (0.12%),60 (1%), glycerine (3%), methyl p-hydroxybenzoate (0.1%),
Propylparaben (0.02%), NaOH (adjust pH to 5.5) and EDTA (0.02%).
Oil phase
Stearic acid (7.5%), castor oil (8%), albolene (6%) and SPAN 60 (2%).
0.125% (preparation based on gel):
Jamaicin (0.125%), ethanol (2.5%), glycerine (10%), Phenoxyethanol (0.3%), carbomer.
0.3% (preparation based on gel):
Jamaicin (0.3%), propane diols (9.25%), PEG 400 (5.03%), methyl p-hydroxybenzoate (0.1%),
Propylparaben (0.02%), NaOH (0.4%), EDTA (0.02%), carbomer940 (1%).
G22 (preparation based on gel):
Jamaicin (0.1%), SDS (0.086%), glycerine (10%),80 (0.5%), P-hydroxybenzoic acid first
Ester (0.1%), propylparaben (0.02%), citric acid (0.033%), Trisodium citrate dihydrate (0.115%),
NaOH, EDTA (0.02%), carbomer940 (0.3%), HEC 250HHX (1.2%).Size distribution:3.83/11.34/
27.24 (in the form of D10/D50/D90, wherein each value refers to the corresponding percentage for being less than the particle of the size, i.e., 10%
Particle is less than 3.83, etc.).
G23 (preparation based on gel):
Jamaicin (0.1%), SDS (0.086%), glycerine (10%),80 (0.5%), P-hydroxybenzoic acid first
Ester (0.1%), propylparaben (0.02%), citric acid (0.033%), Trisodium citrate dihydrate (0.115%),
NaOH, EDTA (0.02%), carbomer940 (0.3%), HEC 250HHX (1.2%).Size distribution:1.45/2.85/9.30
G24 (preparation based on gel):
Jamaicin (0.1%), SDS (0.043%), glycerine (10%),80 (0.5%), P-hydroxybenzoic acid first
Ester (0.1%), propylparaben (0.02%), citric acid (0.033%), Trisodium citrate dihydrate (0.115%),
NaOH, EDTA (0.02%), carbomer940 (0.3%), HEC 250HHX (1.2%).Size distribution:1.55/2.86/5.44
The granularity of G22, G23 and G24 preparation is by following measure.
Prepare pure water, then add Berberine hydrochloride,80 and lauryl sodium sulfate (SDS).It is fully dispersed
Afterwards, mixture is micronized.Afterwards, granularity is measured by diffraction analysis instrument.
Experiment condition
Mouse is put to death by cervical dislocation.Complete thick flank skin is removed, and is placed on the diffusion cell being in contact with acceptor
In, the acceptor is mutually 0.01M PBS (pH 7.4 at 37 DEG C).Buffer solution is pumped across reception with the flow velocity of 3-4mL/h
Device compartment.300 μ l preparations are added on the skin surface in donor compartment.Collect and connect when 0,1,2,3,4,6,8,10 and 12 are small
Device solution is received to analyze for HPLC.Calculated by the slope of the linear segment of accumulation infiltration capacity-time graph of Berberine hydrochloride
Skin flux.
As a result
Fig. 1 shows that small bavin alkali (ng/cm is permeated in the accumulation of all 6 kinds of test formulations2)-time diagram.As can see
, compared with other preparations, C8 (cream preparation) and G23 (preparation based on gel) infiltrations are best.This be it is unexpected, because
For in theory, due to physical property of the jamaicin in water phase, all six kinds of preparations should be with similar rate penetration.
Fig. 2 shows that small bavin alkali (ng/cm is permeated in the accumulation of three kinds of gel mixed suspension preparations (G22, G23 and G24)2)-the time
Figure.As appears, permeability is proportionate with penetration enhancer (SDS), but negatively correlated with jamaicin size.D90
Permeability ratio D90 G22 higher than 10 μm of the jamaicin size less than 10 μm of G23 and G24 height.
Embodiment 2
The minipig penetration study of barberry alkali preparation
Compare following barberry alkali preparation:1) C8, G22 and G23;With 2) 0.125%, 0.30% and G23.
Skin:The skin-grafting of minipig (Lanyu pigs or Lee sung pigs) skin is up to 700 μm, resistance>10kΩ(Millicell-
ERS, Millipore).
Permeability test:
Porcine skin is placed on diffusion cell, corium side is in contact with acceptor, and the acceptor is mutually filled with PBS (at 37 DEG C
pH 7.4).The preparation of 20 μ l is added on skin surface into donor compartment.8 it is small when after, use three dry cotton swabs to remove skin tables
Residual preparation on face.At the end of when small with preparation processing 12 and when 24 is small, skin is removed from diffusion cell, then with three leachings
Water cotton swab carefully cleaning skin surface.Cuticula is removed using 10 adhesive tape stripping methods (tap-stripping).Then by skin
Skin is placed on glass dish, and in 60 DEG C of water-baths thermal release 90 seconds into epidermis and corium.Weigh and shred separated epidermis and true
Skin, and with 0.5ml diluents (1%H3PO4:CH3OH(1:1)) extract.Skin extract is centrifuged into 20min with 14,500rpm.
Berberine hydrochloride concentration in receiver solution and supernatant from skin extract is measured by HPLC.By by known quantity
Medicine be added in skin histology and handled as described above to determine Berberine hydrochloride from the recycling in skin.
As a result
Table 2 summarizes the result of the experiment.
Table 2
Ran for 1 (comparing C8, G22, G23)
Operation 2 (compare 0.125%, 0.30%, G23)
Minipig skin penetration results show:A) C8 (cream preparation) infiltrations are unexpectedly good;B) it is interior when 24 is small, contain
The preparation for having jamaicin particle continuously discharges (G22, G23 are to C8,0.125% and 0.3%);C) compared with C8 (cream preparation),
G22 and G23 (preparation containing jamaicin particle) remain more jamaicins in the epidermis and dermis after 24 hours;D) contain
The preparation for having jamaicin particle permeates more preferably (G23 is to 0.3%) than the preparation containing barberry aqueous slkali;Even if e) G23 containing only
Have 0.1% jamaicin, but compared with 0.3% preparation, 24 it is small when after G23 the jamaicin of nearly identical amounts is remained in epidermis simultaneously
And more jamaicins are remained in the dermis;And f) with other penetration enhancer (ethanol and glycerine in 0.125% preparation
And 0.3% propane diols and PEG 400 in preparation) compare, added in G23 SDS cause permeability increase and epidermis and
The increase of corium Berberine local concentration.
Embodiment 3:
Skin biopsy result of the patient after the topical formulations treatment containing jamaicin
The subject of test is 56 years old male, it receives EGFR inhibitor Afatinib, for treating non-small cell lung
Cancer (NSCLC).After Afatinib is received, subject starts to coagulate using the part of G23 preparations in its facial side once a day
Glue, and at opposite side application vehicle gel (G23 for being free of jamaicin).
The bilateral skin biopsy of subject's nasolabial groove gauffer (both sides of nose) is collected, completes the local treatment of two weeks.It is logical
The incisional biopsy for crossing 1.0cm × 0.5cm obtains skin sample, is then dyed and carried out using h and E (H&E)
Histology processing.Assessed by well-trained dermal pathology scholar.
H&E coloration results (Fig. 3 and 4) are shown, are kept with hair follicle (follicular) structure of the G23 skin areas handled
It is complete and there is no inflammatory cell infiltration (Fig. 3), and the hair follicle structure of the skin handled with vehicle gel is destroyed, in hair follicle
There is massive inflammatory cells infiltrated in all regions, vacuole change (Fig. 4) occurs in the dermal-epidermal junction of follicular epithelium, show barberry
Alkali (G23) is used to treat the potential antiphlogistic effects with the relevant dermal toxicity of EGFR inhibitor.
Embodiment 4:
Facial lesion result after the topical formulations treatment of the included jamaicin of patient
During the treatment of 4 weeks, the half side face of subject for starting to receive Afatinib inhibitor (EGFRI therapies) receives
G23, the other half receives vehicle gel (G23 of no jamaicin).Subject presses 1:1 pro rate determines application study medicine
The facing side of thing.Before or after EGFRI treatments are started in 1 day, subject begins to use research medicine.In the bedtime
(HS) once a day (QD) will study medicament administration to it is facial specify it is half side.
The quantity of facial lesion (papule and warts) is assessed when accessing weekly, schedules to last surrounding.As illustrated in figs. 5-7, find
Following obvious trend:The quantity of the upper lesion of half side face handled with G23 is substantially less than the quantity on the other half, shows small
Bark of a cork tree alkali be used for treat EGFR inhibitor or other targeted therapies induction or immunotherapy induction dermal toxicity potential treatment
Effect.
Claims (17)
1. a kind of method for treating and/or preventing the dermal toxicity induced by targeted therapies and/or immunotherapy, it is included to need
Its patient is wanted to apply the jamaicin or its biology equivalence analog of pharmaceutical effective amount.
2. according to the method described in claim 1, wherein described targeted therapies are selected from the group consisted of:EGFR inhibitor,
More tyrosine kinase (MTK) inhibitor, mek inhibitor, phosphoinositide 3-kinase (PI3K) inhibitor, protein kinase B (AKT) suppression
It is preparation, BRAF inhibitor, HER2 inhibitor, more kinase angiogenesis inhibitors, mTOR inhibitors, ALK/c-met inhibitor, more
Kinases Abl inhibitor, BTK inhibitor, hdac inhibitor, proteasome inhibitor and rxr agonist.
3. according to the method described in claim 1, wherein described immunotherapy is selected from the group consisted of:It is cancer vaccine, thin
Intracellular cytokine reagent, cell therapy, immunologic test point protein inhibitor and immunologic test point albumen stimulant.
4. according to the method described in claim 1, wherein described dermal toxicity is selected from group consisting of:Papulopustular rash,
Plaque-like papule, erythema, telangiectasis flush, paronychia and cracking, hair change, axersis, catarrh, pruritus and hand
Skin of foot reacts.
5. according to the method described in claim 1, the bioequivalence analog of wherein described jamaicin is selected from what is consisted of
Group:Jateorrhizine, palmatine, coptisine, 9- demethyls jamaicin, 9- demethyls palmatine, 13- hydroxyls jamaicin, berberrubine,
The red alkali of palmatine, 9-O- ethyls berberrubine, 9-O- ethyl -13- ethyls berberrubine, 13- methyl dihydroberberine N- methyl
Salt, Tetrahydro-proto-berberines and its N- methyl salts and 9- lauryl berberrubine chlorides.
6. according to the method described in claim 1, the bioequivalence analog of wherein described jamaicin is palmatine or coptisine.
Treated and/or the method for dermal toxicity that prevention is induced by targeted therapies and/or immunotherapy 7. a kind of, it include to by
The local medicine composition of the local skin application pharmaceutical effective amount of infection, the local medicine composition include jamaicin or
Its biology equivalence analog.
8. according to the method described in claim 7, wherein described targeted therapies are selected from the group consisted of:EGFR inhibitor,
More tyrosine kinase (MTK) inhibitor, mek inhibitor, phosphoinositide 3-kinase (PI3K) inhibitor, protein kinase B (AKT) suppression
It is preparation, BRAF inhibitor, HER2 inhibitor, more kinase angiogenesis inhibitors, mTOR inhibitors, ALK/c-met inhibitor, more
Kinases Abl inhibitor, BTK inhibitor, hdac inhibitor, proteasome inhibitor and rxr agonist.
9. according to the method described in claim 7, wherein described immunotherapy is selected from the group consisted of:It is cancer vaccine, thin
Intracellular cytokine reagent, interferon, interleukin 2, cell therapy, immunologic test point protein inhibitor and immunologic test point albumen thorn
Swash thing.
10. according to the method described in claim 7, wherein described dermal toxicity is selected from group consisting of:Papulopustular rash,
Plaque-like papule, erythema, telangiectasis flush, paronychia and cracking, hair change, axersis, catarrh, pruritus and hand
Skin of foot reacts.
11. according to the method described in claim 7, the bioequivalence analog of wherein described jamaicin is selected from what is consisted of
Group:Jateorrhizine, palmatine, coptisine, 9- demethyls jamaicin, 9- demethyls palmatine, 13- hydroxyls jamaicin, berberrubine,
The red alkali of palmatine, 9-O- ethyls berberrubine, 9-O- ethyl -13- ethyls berberrubine, 13- methyl dihydroberberine N- methyl
Salt, Tetrahydro-proto-berberines and its N- methyl salts and 9- lauryl berberrubine chlorides.
12. according to the method described in claim 7, the bioequivalence analog of wherein described jamaicin is palmatine or the coptis
Alkali.
13. according to the method described in claim 7, wherein described local medicine composition includes at least barberry of 0.02%w/w
Alkali or its biology equivalence analog.
14. according to the method described in claim 7, wherein described local medicine composition includes about 0.1% to about 2%w/w's
Jamaicin or its biology equivalence analog.
15. according to the method described in claim 7, wherein described jamaicin or its biology equivalence analog are main pharmacy
Upper acceptable active component.
16. according to the method described in claim 7, wherein described jamaicin or its biology equivalence analog are unique pharmacy
Upper acceptable active component.
17. according to the method described in claim 7, wherein described local medicine composition is lotion, cream, ointment, paste
Agent, gel, spray, supensoid agent, emulsion, foaming agent, patch, the form of pulvis and liniment.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184024P | 2015-06-24 | 2015-06-24 | |
US62/184,024 | 2015-06-24 | ||
US15/161,576 | 2016-05-23 | ||
US15/161,576 US20160263092A1 (en) | 2013-12-19 | 2016-05-23 | Therapeutic uses of berberine formulations |
PCT/US2016/039180 WO2016210230A1 (en) | 2015-06-24 | 2016-06-24 | Therapeutic uses of berberine formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107921284A true CN107921284A (en) | 2018-04-17 |
Family
ID=57586436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680049200.3A Pending CN107921284A (en) | 2015-06-24 | 2016-06-24 | The therapeutical uses of barberry alkali preparation |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3313520A4 (en) |
JP (1) | JP2018518507A (en) |
KR (1) | KR20180020229A (en) |
CN (1) | CN107921284A (en) |
AU (1) | AU2016282800A1 (en) |
BR (1) | BR112017027897A2 (en) |
CA (1) | CA2990237A1 (en) |
HK (1) | HK1249068A1 (en) |
IL (1) | IL256400A (en) |
MX (1) | MX2018000262A (en) |
RU (1) | RU2733743C2 (en) |
TW (1) | TW201713334A (en) |
WO (1) | WO2016210230A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109806264A (en) * | 2019-04-10 | 2019-05-28 | 江苏海钥医药科技有限公司 | Pharmaceutical composition and its application |
CN109999034A (en) * | 2019-02-11 | 2019-07-12 | 浙江理工大学 | Oncoprotein TNIK kinases targets natural small molecule inhibitor and its application |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020505362A (en) * | 2017-01-19 | 2020-02-20 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドTWI Biotechnology, Inc. | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory skin disorders |
CA3085013A1 (en) | 2017-12-13 | 2019-06-20 | Onquality Pharmaceuticals China Ltd. | A method for preventing or treating egfr-inhibition associated diseases |
CN114028568A (en) | 2018-04-16 | 2022-02-11 | 上海岸阔医药科技有限公司 | Method for preventing or treating side effects of tumor therapy |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008356A (en) * | 1998-04-24 | 1999-12-28 | Hanwha Corporation | Pharmaceutically available protoberberine salts derivatives, and protoberberine salts derivatives, and protoberberine derivatives and salts thereof |
EP1080719A2 (en) * | 1999-09-03 | 2001-03-07 | Active Organics Inc. | Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids |
US20060269485A1 (en) * | 2002-11-29 | 2006-11-30 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
CN102481290A (en) * | 2009-06-30 | 2012-05-30 | 德安生医有限公司 | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
WO2015095640A1 (en) * | 2013-12-19 | 2015-06-25 | Twi Biotechnology, Inc. | Berberine formulations and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7404967B2 (en) * | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
US5760096A (en) * | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
US6440465B1 (en) | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
US20040146539A1 (en) | 2003-01-24 | 2004-07-29 | Gupta Shyam K. | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits |
US7205006B2 (en) * | 2003-09-25 | 2007-04-17 | Prime Pharmaceutical Corporation | Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same |
CN1893911B (en) | 2003-11-17 | 2010-12-29 | 赛德玛公司 | Formula including tetrapeptide and tripeptide mixture |
US20050158404A1 (en) | 2003-11-18 | 2005-07-21 | Goodless Dean R. | Composition and method for treatment of acne |
-
2016
- 2016-06-24 TW TW105120086A patent/TW201713334A/en unknown
- 2016-06-24 KR KR1020187001673A patent/KR20180020229A/en not_active Application Discontinuation
- 2016-06-24 WO PCT/US2016/039180 patent/WO2016210230A1/en active Application Filing
- 2016-06-24 RU RU2018102700A patent/RU2733743C2/en active
- 2016-06-24 EP EP16815356.7A patent/EP3313520A4/en not_active Withdrawn
- 2016-06-24 BR BR112017027897A patent/BR112017027897A2/en not_active Application Discontinuation
- 2016-06-24 AU AU2016282800A patent/AU2016282800A1/en not_active Abandoned
- 2016-06-24 CA CA2990237A patent/CA2990237A1/en not_active Abandoned
- 2016-06-24 MX MX2018000262A patent/MX2018000262A/en unknown
- 2016-06-24 JP JP2017566661A patent/JP2018518507A/en active Pending
- 2016-06-24 CN CN201680049200.3A patent/CN107921284A/en active Pending
-
2017
- 2017-12-18 IL IL256400A patent/IL256400A/en unknown
-
2018
- 2018-07-10 HK HK18108954.7A patent/HK1249068A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008356A (en) * | 1998-04-24 | 1999-12-28 | Hanwha Corporation | Pharmaceutically available protoberberine salts derivatives, and protoberberine salts derivatives, and protoberberine derivatives and salts thereof |
EP1080719A2 (en) * | 1999-09-03 | 2001-03-07 | Active Organics Inc. | Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids |
US20060269485A1 (en) * | 2002-11-29 | 2006-11-30 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
CN102481290A (en) * | 2009-06-30 | 2012-05-30 | 德安生医有限公司 | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
WO2015095640A1 (en) * | 2013-12-19 | 2015-06-25 | Twi Biotechnology, Inc. | Berberine formulations and uses thereof |
CN106163280A (en) * | 2013-12-19 | 2016-11-23 | 安成生物科技股份有限公司 | Berberine preparation and application thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109999034A (en) * | 2019-02-11 | 2019-07-12 | 浙江理工大学 | Oncoprotein TNIK kinases targets natural small molecule inhibitor and its application |
CN109806264A (en) * | 2019-04-10 | 2019-05-28 | 江苏海钥医药科技有限公司 | Pharmaceutical composition and its application |
CN109806264B (en) * | 2019-04-10 | 2021-04-02 | 江苏海钥医药科技有限公司 | Pharmaceutical composition and application thereof |
Also Published As
Publication number | Publication date |
---|---|
RU2018102700A (en) | 2019-07-25 |
WO2016210230A1 (en) | 2016-12-29 |
AU2016282800A1 (en) | 2018-02-01 |
IL256400A (en) | 2018-02-28 |
BR112017027897A2 (en) | 2018-08-28 |
RU2733743C2 (en) | 2020-10-06 |
EP3313520A4 (en) | 2019-01-02 |
HK1249068A1 (en) | 2018-10-26 |
TW201713334A (en) | 2017-04-16 |
RU2018102700A3 (en) | 2019-12-03 |
EP3313520A1 (en) | 2018-05-02 |
MX2018000262A (en) | 2018-03-08 |
JP2018518507A (en) | 2018-07-12 |
KR20180020229A (en) | 2018-02-27 |
CA2990237A1 (en) | 2016-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107921284A (en) | The therapeutical uses of barberry alkali preparation | |
US10213418B2 (en) | Therapeutic uses of berberine formulations | |
Lin et al. | Efficacy and safety of Indigo naturalis extract in oil (Lindioil) in treating nail psoriasis: a randomized, observer-blind, vehicle-controlled trial | |
Rafati et al. | Nigella sativa L. for prevention of acute radiation dermatitis in breast cancer: A randomized, double-blind, placebo-controlled, clinical trial | |
JP2017500347A (en) | Berberine preparation and use thereof | |
CN108289858A (en) | The not special local Injectable composition of auspicious quinoline for treating neoplastic cutaneous diseases | |
CN101406564A (en) | External-use Chinese medicinal composition formulation and uses thereof | |
CN104546928A (en) | Traditional Chinese medicinal composition for treating infantile diaper rash and preparation method of traditional Chinese medicinal composition | |
CN102872288B (en) | Frankincense rheumatism aerosol for curing rheumatism bone ache and preparation method thereof | |
CN107441071B (en) | A kind of application of ar-turmerone in preparation treatment and/or prevention psoriasis | |
CN102319272B (en) | Application of ginkgolic acid in preparation of external preparation for treating dermatopathy | |
CN102872158B (en) | External drug combination for curing eczema and preparation method thereof | |
CN103877250B (en) | A kind ofly treat Chinese medicine composition of skin eczema pruritus and preparation method thereof | |
KR20160083299A (en) | Ointment composition of the aerial part of Glechoma grandis Kuprianova var. longituba Kitagawa on scalded wound healing | |
CN108403932A (en) | A kind of Chinese medicine compound prescription external preparation and its preparation method and application for treating steroid dependent dermatitis | |
CN104394867B (en) | Containing purine derivative or the compositions for preventing or treat allergic dermatitis of its salt | |
Lesher et al. | Tinea corporis | |
Swenor | Is permethrin 5% cream effective for rosacea? | |
CN108969531A (en) | Polyethylene glycol is preparing application and its drug in curing psoriasis drug as active constituent | |
CN103751231A (en) | Application of gingko extract nanometer liposome in acne removing and dermatosis treatment | |
Gavrilova et al. | Follicular acneiform eruption induced by bevacizumab | |
CN105125683B (en) | A kind of pharmaceutical treatment of psoriasis and preparation method thereof | |
JPH03112931A (en) | Remedy for psoriasis bulgaris | |
CN107693608A (en) | A kind of Chinese and Western for treating eczema combines pharmaceutical preparation and preparation method thereof | |
CN110664793A (en) | Application of 3-hydroxy-5-substituted benzoic acid in preparing external medicine for treating eczema, dermatitis and psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1249068 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180417 |